Pulmonx Corporation (NASDAQ: LUNG) has reported its second-quarter 2025 financial results and provided updated full-year guidance, along with plans for upcoming investor engagements.

**Recent Financial Performance and Outlook**
*   For the second quarter of 2025, Pulmonx reported total worldwide revenue of $23.9 million, marking a 15% increase year-over-year.
*   International revenue showed strong growth at $9.1 million, a 32% year-over-year increase.
*   U.S. revenue grew by a more modest 6% year-over-year to $14.7 million, which was below the company's expectations.
*   The company's gross margin for Q2 2025 was 72%, a decrease from 74% in the second quarter of 2024.
*   Pulmonx reported a net loss of $15.2 million, or $0.38 per share, for the second quarter of 2025, which was a slight improvement from a net loss of $15.3 million ($0.39 per share) in the same period last year.
*   Adjusted EBITDA loss for Q2 2025 was $8.4 million, an increase from $7.6 million in Q2 2024.
*   As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $84.2 million.
*   Due to slower-than-expected U.S. revenue conversion, Pulmonx revised its full-year 2025 revenue guidance down to a range of $90 million to $92 million, from its previous forecast of $96 million to $98 million.
*   The company anticipates a full-year 2025 gross margin of approximately 74% and expects operating expenses to be in the range of $128 million to $130 million, a reduction from prior guidance.

**Operational Developments**
*   In the second quarter of 2025, Pulmonx engaged over 20,000 first-time patients through direct-to-patient advertising efforts.
*   During the same period, 12 new U.S. treatment centers were added, and 26 new physicians were trained.
*   The company's ZephyrÂ® Valve, which is FDA-approved as a "breakthrough device," is commercially available in more than 25 countries and is considered a standard of care for severe emphysema.

**Upcoming Investor Engagements**
*   Pulmonx is scheduled to participate in two investor conferences in September 2025: the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11.